OBJECTIVE: Bevacizumab (BV), a monoclonal antibody for the treatment of recurrence of glioblastoma, was approved in 2009 in USA whereas today no such approval there is in the European Union. BV showed a higher response rates and prolongation of median at 6 month progression free survival (PFS) compared with historical treatment. The aim of this study was to evaluate the clinical benefit (CB) of BV therapy alone or in combination in the treatment of recurrent glioma (RG) .
METHODS: Data of RG patients treated with BV alone or in combination treated in two Italian Center (National Cancer Institute Regina Elena of Rome and Department of Clinical and Experimental Oncology of PADUA) since 2012 were collected. CB was evaluated measuring reduction of steroid and improvement of Karnosfy Performance Status (KPS) of at least 20 point.
RESULTS: We enrolled 138 RG treated with BV. Of them 52 are female (37%) and 87 are males (63%). The majority of patients were glioblastoma (N=112, 91%) previously treated with three lines of chemotherapy before BV (n=103). At enrollment 113 patients was receiving steroid. 60% of patients showed reduction of steroids dose (in 94% after the first infusion of BV). A CB was observed in 62% of patients without significant differences between patients treated with BV alone or in combination. Also 27 patients presenting progression disease at MRI showed a CB in (42%) during the treatment. Patients with a CB showed a rate of progression free survival (PFS) at 1 years of 17.6%, significantly higher (p 0.0001) than patients without CB. Also OS resulted significantly different (p=0.0009) between group with CB (rate of OS at 1 years 37.9%) respect patients without CB 14.1%.
DISCUSSION: In this study the majority of patients treated with BV reported a clinical benefit, even in those showing radiographic progression. Moreover, patients with clinical benefit showed a better rate of progression free survival at 1 year and a longer survival. Our results confirm the role of BV in the treatment of recurrent glioma and the favourable impact on patients clinical symptoms. One of the key problems when treating patients with malignant gliomas is that despite being able to remove the major bulk of the tumour, tumour cells have already spread to local and distant sites of the brain. Previous glioblastoma models used in animals have lately been questioned, not least since they do not have an infiltrative growth pattern, and some are more similar to a sarcoma. We here present our new tumour model NS1, which is is easily detectable since all cells express GFP, and which has an infiltrative growth. We mean that this model can serve as an important tool in order to better understand glioblastoma growth and treatment in rats.
NS1 was developed through ENU treatment of homozygous Fischer 344 rats during pregnancy. The cell line was developed after culturing the tumour cells from one offspring with CNS tumour, and it could grow intracerebrally as well as subcutaneously and generate tumours in GFP negative animals. With FACS analysis we could detect GFP expression, as expected, in the GFP positive cells. The tumour cells had a strong RNA expression for wt IDH1 and EGFR.
With htx-eosin staining, a cell rich tumour could be identified. GFAP staining was positive. After perfusion fixation of the brains, we could identify clear fluroescence of the tumours in fluroescence microscope, and we could show an infiltrative growth pattern. This picture was confirmed with GFP immunohistochemistry.
Animal series have been done, and we have shown that inoculation of 5000 NS1 cells in the caudate nucleas reliably gives rise to tumour causing the death of the host animal around day 20 after inoculation. We are now starting a series of MRI scannings as well, in order to further investigate the growth pattern.
We mean that with this new model, glioblastomas in rats could be studied much better as compared to some of the old cell lines. Our model is easy to track thanks to the GFP expression in all cells, it has an infiltrative growth pattern and can be investigated directly under fluorescence microscope without the extra steps otherwise needed to demonstrate tumour growth. We feel that this is really an important tool for further studies, not only at our own laboratory. A major advantage with this model is that it can be used in fully immunocompetent animals, which is otherwise a problem when reasearchers want to combine GFP-expressing tumour cells and immunotherapy studies. MATERIALS AND METHODS: MTH1 expression was analyzed in human glioma specimens by quantitative RT-PCR, immunohistochemistry and Western Blot. U87 cell migration in vitro and tumor growth in an orthotopic rat model was monitored after knock-down of MTH1 by siRNA or inhibition by crizotinib. In addition, progression free survival of patients was correlated to the MTH1 level.
P08.67 INHIBITION OF MUTT HOMOLOG 1 (MTH1) IN GLIOBLASTOMA MULTIFORME RESULTS IN IMPAIRED CELL MIGRATION AND TUMOR GROWTH
RESULTS: Higher expression of MTH1 was observed in glioblastoma than in lower grade astrocytomas (p<0.05) and peritumoral tissue, both, on the gene and protein level. MTH1 siRNA transfected U87 cells showed slower migration compared to control U87 cells (p<0.01). Furthermore, treatment with crizotinib, an inhibitor of MTH1, also lowered cell migration. In rats, tumor growth was significantly impaired in MTH1 siRNA U87 grafts (p<0.01).
DISCUSSION: These results show that MTH1 might play an essential role in both, malignization of glioma and disease progression in recurrent glioblastoma. Moreover, the MTH1 level in patients seems to influence tumor growth and could be targeted by crizotinib indicating a role for potential future therapies. INTRODUCTION: Numerous studies on different non-brain cancers indicate Ran (Ras-related nuclear protein), a key protein in the nucleoplasmic transport during interphase and the regulation of mitotic spindle formation, to be involved in tumorigenesis, cancer progression and tumor cell survival. It further is predictive for poor outcome.
P08.68 THE RAN SIGNALING PATHWAY IS UPREGULATED
Overexpression of Ran has been reported in glioblastoma [GBM] tissue. To further evaluate the role of the Ran signaling pathway in astrocytoma, we measured the expression of its key components Ran, RCC1, RANBP1 and RANBP2 in different types of brain tumor tissue.
MATERIALS AND METHODS: Using qRT-PCR and Western blot analysis the gene and protein expression was analyzed in 80 tissue samples. The tissue subtypes were astrocytomas WHO II°, anaplastic astrocytomas, primary and secondary glioblastomas and tissue samples after recurrence subsequent to radiochemotherapy. Peritumoral brain tissue was used as a control. For PCR analysis at least 10 glioma probes and for Western blot analysis at least 6 glioma probes were used per group. RESULTS: Ran protein overexpression compared to non-neoplastic brain was detected in anaplastic astrocytomas (90%), primary glioblastoma (140%) and secondary glioblastoma (170%). With increasing WHO grade there was an increase of Ran mRNA expression and chemoradiation therapy led to further enhanced expression in primary and secondary glioblastoma (from 1.36 to 2.25 and from 2.08 to 3.08 arbitrary unites [AU], respectively). There was also an increase in gene expression of RCC1, RANBP1 and RANBP2 analogue to that of Ran: showing a steady increase with higher WHO grading. Correspondingly to Ran, gene expression of RCC1 increased in primary and secondary glioblastoma recurrent after radiochemotherapy from 3.19 to 3.87 AU and from 4.14 to 10.11 AU respectively as well as that of RANBP2 from 2.36 to 5.14 AU and from 2.77 to 4.74 AU respectively. DISCUSSION: Our data clearly show a grade dependent upregulation of key components of the Ran pathway in astrocytomas and a further increase after radiochemotherapy. Therefore, this pathway may represent a future target for glioblastoma therapy.
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